A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Vedolizumab (Primary) ; Vedolizumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 01 Dec 2017 Planned End Date changed from 3 Sep 2020 to 10 Dec 2019.
    • 01 Dec 2017 Planned primary completion date changed from 3 Mar 2020 to 21 Jun 2019.
    • 29 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top